List of Clinical Studies


Gynecologic Oncology - Cervical Cancer

Study Name	Principal Investigator

MK3475-826 – A phase 3 randomized, double-blind, placebo-controlled study of Pembrolizumab (MK3475) plus chemotherapy vs. chemotherapy plus placebo for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826). Read more.	Sharyn Lewin, MD

Gynecologic Oncology - Endometrial Cancer

Study Name	Principal Investigator

MK7902-001 – A Multicenter, Open-label, Randomized Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab versus Treatment of Physician’s Choice in Participants with Advanced Endometrial Cancer. Hypothesis is that combination therapy leads to improved progression-free survival. Read more.	Sharyn Lewin, MD

MK3475-775 – A Phase 3 Randomized, Open-label, Study of Pembrolizumab (MK-3475) Plus Levantinib versus Chemotherapy for First-Line Treatment of Advanced or Recurrent Endometrial Carcinoma. Hypothesis is that the combination for pembrolizumab plus Levantinib is superior to chemotherapy with respect to progression-free survival. Read more.	Sharyn Lewin, MD

Gynecologic Oncology - Mixed Cancer Indication

Study Name	Principal Investigator

MIRASOL – A randomized, open-label, phase 3 study of Mirvetuximab Soravtansine vs. investigator's choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. Read more.	Sharyn Lewin, MD

LIGHT – Non-randomized, open-label phase 2 study to assess Olaparib tablets as a treatment for subjects with different HRD tumors status and with platinum-sensitive, relapsed, high-grade serous or high-grade endometrial, ovarian, fallopian tube, or primary peritoneal cancer that have received at least 1 prior line of chemotherapy. Read more.	Sharyn Lewin, MD

IMAGYN050 – A phase 2, multicenter, randomized, placebo-controlled study of Atezolizumab vs. placebo in combination with Paclitaxel, Carboplatin, and Bevacizumab for patients with newly diagnosed stage iii/iv ovarian, fallopian tube, or primary peritoneal cancer. Read more.	Sharyn Lewin, MD

Gynecologic Oncology - Ovarian Cancer

Study Name	Principal Investigator

FIRST – A Randomized, double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer. Hypothesis is that TSR-042 and Niraparib produces a deeper response and prolonged progression-free survival. Read more.	Sharyn Lewin, MD

MK7339-001 – A randomized phase 3, double-blind study of chemotherapy with or without Pembrolizumab followed by maintenance with Olaparib or placebo for the first-line treatment of BRCA non-mutated advanced epithelial ovarian cancer. Read more.	Maria Schiavone, MD

We are open.
We are clean.
We are ready.

Medical Care

Cancer Care

Specialty Services

Medical Care & Treatments

Patients & Visitors

For Patients

For Visitors

Directions & Parking

Amenities & Services

Community Health

About Holy Name Medical Center

Quick Links

Key Phone Numbers

Medical Center Operator

Physician Referral Service

Patient Information

Foundation (Donations)

Human Resources

Medical Staff Office

In This Section

For More Information:

List of Clinical Studies

We are open.We are clean.We are ready.

Medical Care

Cancer Care

Specialty Services

Medical Care & Treatments

Patients & Visitors

For Patients

For Visitors

Directions & Parking

Amenities & Services

Community Health

About Holy Name Medical Center

Quick Links

Key Phone Numbers

Medical Center Operator

Physician Referral Service

Patient Information

Foundation (Donations)

Human Resources

Medical Staff Office

List of Clinical Studies

In This Section

For More Information:

List of Clinical Studies

We are open.
We are clean.
We are ready.